5 results on '"Damam Srinivasulu"'
Search Results
2. Nutritional anemia as a cause of reversible blindness
- Author
-
V Anusha, Damam Srinivasulu, M Ranganath, and Kotapati Poornima
- Subjects
Pediatrics ,medicine.medical_specialty ,Blindness ,genetic structures ,Anemia ,business.industry ,lcsh:R ,lcsh:Medicine ,medicine.disease ,Pancytopenia ,Roth spots ,anemic retinopathy ,eye diseases ,pancytopenia ,Iron-deficiency anemia ,hemic and lymphatic diseases ,medicine ,Vitamin B12 ,roth spots ,business ,Nutritional anemia ,b12 deficiency ,Retinopathy - Abstract
We report a case of 42-year-old male presented with acute onset breathlessness and blurring of vision in both eyes. Upon evaluation, the patient is found to have vitamin B12 and iron deficiency anemia; ophthalmoscopic examination revealed bilateral preretinal hemorrhages and Roth spots. This case documents the occurrence of retinopathy in nutritional dimorphic anemia causing blindness which is reversible after correction of anemia.
- Published
- 2020
3. Symptomatic reinfection of SARS-CoV-2 with spike protein variant N440K associated with immune escape
- Author
-
Vinod Scaria, Juturu Vijaya Lakshmi, A. Surekha, Pulala Chandrasekhar, Bani Jolly, Abhinav Jain, Mohamed Imran, Vigneshwar Senthivel, P. R. Vanaja, Pallavali Roja Rani, Mohit Kumar Divakar, Sridhar Sivasubbu, Damam Srinivasulu, and Rahul C. Bhoyar
- Subjects
Male ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,SARS-CoV-2 ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Immune escape ,COVID-19 ,Spike Protein ,Genome, Viral ,Middle Aged ,Biology ,Antibodies, Viral ,Antibodies, Neutralizing ,Virology ,Infectious Diseases ,Reinfection ,Spike Glycoprotein, Coronavirus ,Humans ,Letters to the Editor ,Letter to the Editor ,Immune Evasion - Abstract
Here we describe a case of re-infection in an individual from South India characterized by whole genome sequencing of the virus isolated from both episodes. The analysis shows the presence of an immune escape variant N440K in the Spike protein in both episodes of infection. Incidentally, this variant was also found in a case of reinfection previously reported by us in a healthcare worker from North India
- Published
- 2021
- Full Text
- View/download PDF
4. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)
- Author
-
Agarwal, Anup, Mukherjee, Aparna, Kumar, Gunjan, Chatterjee, Pranab, Bhatnagar, Tarun, Malhotra, Pankaj, Latha, B, Bundas, Sunita, Kumar, Vivek, Dosi, Ravi, Khambholja, Janak Kumar, de Souza, Rosemarie, Mesipogu, Raja Rao, Srivastava, Saurabh, Dube, Simmi, Chaudhary, Kiran, Subash, S, Anbuselvi, S, Rajendran, V, Sundararajaperumal, A, Balamanikandan, P, Maheswari, R S Uma, Jayanthi, R, Ragunanthanan, S, Bhandari, Sudhir, Singh, Ajeet, Pal, Ashok, Handa, Anjali, Rankawat, Govind, Kargirwar, Ketan, Regi, Joyce, Rathod, Darshana, Pathrose, Edwin, Bhutaka, Nirankar, Patel, Mayur H, Verma, Rahul J, Malukani, Kamal, Patel, Shivani, Thakur, Apurv, Joshi, Satish, Kulkarni, Rashmi, Suthar, Nilay N, Shah, Nehal M, Purohit, Hemang M, Shah, Cherry K, Patel, Monila N, Shah, Saket, Shah, Smit T, Memon, Tehsim, Beriwala, Vishal R, Jashnani, Kusum, Ezzy, Fatema, Agrawal, Simran, Bhadade, Rakesh, Atish, MN, Madke, Tushar, Kavishwar, Vikas, Waghmare, Ramesh, Valvi, Nitin, Chander, B Thrilok, Sekhar, A Vinaya, Maurya, Akhilesh Kumar, Hemanth, K, Nagamani, K, Sudha, K, Chandra, T Ravi, Rao, K Tushara, Vyshnavi, J, Upadhyay, Rashmi, Bahadur, Shalini, Pathak, Rambha, Seth, Shikha, Gupta, Rakesh, Saxena, Rita, Dwivedi, Preksha, Malik, Reeni, Chourasia, Deepti, Lalwani, Jaya, Sharma, UM, Marko, JL, Suri, Amit, Kumar, Vijay, Kaushik, Rajnish, Kodan, Parul, Acharya, Bhabani Prasad, Gaur, Kuldeep Kumar, Gupta, Anubhav, Sachdeva, Prerna, Dogra, Shruti, Jindal, Aikaj, John, M Joseph, Dhanju, Avtar Singh, Khetrepal, Ranjana, Sharma, Neeraj, Kukar, Neetu, Kavita, Divya, Kumar, Rajesh, Mahajan, Rajesh, Singh, Gurpreet, Kaur, Jaspreet, Singh, Raminder Pal, Bassi, Rajni, Parikh, Swapneil, Shrivastav, Om, Shastri, Jayanthi, Desai, Maherra, Udupa, Shreevatsa, Bafna, Varun A, Barge, Vijay, Madane, Rajendra, Yadav, Sheetal, Misra, Sanjeev, Bajpayee, Archana, Garg, M K, Bohra, G K, Nag, Vijaylakshmi, Anne, Puneeth Babu, Nadeem, Mohd, Singh, Pallavi, Niwas, Ram, Khaire, Niranjan Shiwaji, Sharma, Rattiram, Singh, Mini P, Sachdeva, Naresh, Sachdev, Suchet, Hans, Rekha, Suri, Vikas, Yaddanapudi, LN, Lakshmi, PVM, Singh, Neha, Bhushan, Divendu, Kumar, Neeraj, Tambe, Muralidhar, Salvi, Sonali, Kadgi, Nalini, Sangle, Shashikala, Nakate, Leena, Joshi, Samir, Karyakarte, Rajesh, Goyanka, Suraj, Sharma, Nimisha, Verma, Nikhil, Das, Asim, Bahl, Monika, Wadhwa, Nitya, Bhat, Shreepad, Deshmukh, Shweta, Wagh, Vrushali, Kulkarni, Atul, Yardi, Tanvi, Kalgud, Ram S, Reddy, Purushottam, Yevoor, Kavitha, Gajula, Prashanth, Maleyur, Vivek, Medini, S, Mohith, HN, Gurtoo, Anil, Sud, Ritika, Pahuja, Sangeeta, Prakash, Anupam, Gogoi, Parijat, Shukla, Shailja, Reddy, D Himanshu, Chandra, Tulika, Pandey, Saurabh, Maurya, Pradeep, Ali, Wahid, Upadhyay, Kamlesh, Bhatnagar, Nidhi, Shah, Nilima, Shah, Mamta, Patel, Tarak, Jaiswal, Ram Mohan, Jain, Ashish, Sharma, Shweta, Rijhwani, Puneet, Gupta, Naveen, Patel, Tinkal C, Solu, Mahesh G, Patel, Jitendra, Shah, Yash R, Jarag, Mayur, Godbole, Varsha, Shah, Meenakshi, Raj, Rikin, Nagori, Irfan, Jha, Pramod R, Shah, Arti D, Yeeli, Gowtham, Jain, Archit, Gill, Rooppreet Kaur, Babu, KV Sreedhar, Babu, B Suresh, Mohan, Alladi, Vengamma, B, Sekhar, K Chandra, Damam, Srinivasulu, Narsimhulu, K, Aparna, C, Baleswari, G, Reddy, K Ravindranath, Chandrasekhar, P, Panjwani, Sunil Jodharam, Shah, Pragnesh H, Barvaliya, Manish, Desai, Kairavi, Akholkar, Pankaj J, Baldi, Milind, Yadav, Ashok, Gupta, Manoj, Rawat, Nitin, Chawda, Dilip, Natarajan, M, Sintha, M, Kumar, David Pradeep, Rabbani, Fathhur, Khadke, Vrushali Khirid, Patki, Dattatray, Marathe, Sonali, D’Souza, Clyde, Tadha, Vipul, Arora, Satyam, Gupta, Devendra Kumar, Dua, Seema, Chauhan, Nitu, Chahar, Ajeet Singh, Mammen, Joy John, Kumar, Snehil, Daniel, Dolly, Singh, Ravindraa, Dhat, Venkatesh, Agarwal, Yogesh, Arora, Sohini, Pathak, Ashish, Purohit, Manju, Sharma, Ashish, Sharma, Jayashree, Madkaikar, Manisha, Joshi, Kavita, Yadav, Reetika Malik, Bhagwat, Swarupa, Karnik, Niteen D, Gokhale, Yojana A, Naik, Leena, Margam, Sangita, Das, Santasabuj, Turuk, Alka, Kumar, V Saravana, Kanagasabai, K, Sabarinathan, R, Deshpande, Gururaj, Sharma, Sharda, Gunjikar, Rashmi, Shete, Anita, Phagiwala, Darpan, Patil, Chetan, Shingade, Snehal, Jarande, Kajal, Kaushal, Himanshu, Yadav, Pragya, Sapkal, Gajanan, and Abraham, Priya
- Subjects
Adult ,Male ,medicine.medical_specialty ,Pneumonia, Viral ,India ,030204 cardiovascular system & hematology ,Antibodies, Viral ,Corrections ,law.invention ,Betacoronavirus ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Fraction of inspired oxygen ,Internal medicine ,medicine ,Humans ,Treatment Failure ,Pandemics ,COVID-19 Serotherapy ,030304 developmental biology ,Oxygen saturation (medicine) ,0303 health sciences ,SARS-CoV-2 ,business.industry ,Research ,Immunization, Passive ,Absolute risk reduction ,COVID-19 ,General Medicine ,Middle Aged ,Antibodies, Neutralizing ,Confidence interval ,Clinical trial ,Relative risk ,Disease Progression ,Arterial blood ,Female ,Coronavirus Infections ,business - Abstract
ObjectiveTo investigate the effectiveness of using convalescent plasma to treat moderate coronavirus disease 2019 (covid-19) in adults in India.DesignOpen label, parallel arm, phase II, multicentre, randomised controlled trial.Setting39 public and private hospitals across India.Participants464 adults (≥18 years) admitted to hospital (screened 22 April to 14 July 2020) with confirmed moderate covid-19 (partial pressure of oxygen in arterial blood/fraction of inspired oxygen (PaO2/FiO2) ratio between 200 mm Hg and 300 mm Hg or a respiratory rate of more than 24/min with oxygen saturation 93% or less on room air): 235 were assigned to convalescent plasma with best standard of care (intervention arm) and 229 to best standard of care only (control arm).InterventionsParticipants in the intervention arm received two doses of 200 mL convalescent plasma, transfused 24 hours apart. The presence and levels of neutralising antibodies were not measured a priori; stored samples were assayed at the end of the study.Main outcome measureComposite of progression to severe disease (PaO2/FiO2ResultsProgression to severe disease or all cause mortality at 28 days after enrolment occurred in 44 (19%) participants in the intervention arm and 41 (18%) in the control arm (risk difference 0.008 (95% confidence interval −0.062 to 0.078); risk ratio 1.04, 95% confidence interval 0.71 to 1.54).ConclusionConvalescent plasma was not associated with a reduction in progression to severe covid-19 or all cause mortality. This trial has high generalisability and approximates convalescent plasma use in real life settings with limited laboratory capacity. A priori measurement of neutralising antibody titres in donors and participants might further clarify the role of convalescent plasma in the management of covid-19.Trial registrationClinical Trial Registry of India CTRI/2020/04/024775.
- Published
- 2020
- Full Text
- View/download PDF
5. Concurrent occurrence of both intracranial and intramedullary tuberculomas
- Author
-
Dara, Chennakesavulu, primary, Diguvinti, Sreeramulu, additional, Ubara, KiranKumar, additional, and Damam, Srinivasulu, additional
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.